Vaccination and Heart Health: What the Flu Vaccine Really Prevents

The flu vaccine is not a vaccine “against heart attacks.” Its primary purpose is to prevent influenza and reduce its complications. That prevention matters to the heart because an acute respiratory infection can raise inflammation, coagulation, oxygen demand and cardiac workload, triggering an event in a vulnerable person.

The short answer is that influenza vaccination belongs in cardiovascular prevention for people with heart disease or high risk, but it does not replace statins, blood-pressure treatment, smoking cessation, exercise or emergency care for symptoms. The size of benefit depends on baseline risk, and the strongest evidence comes from people with cardiovascular disease, especially after a recent acute coronary syndrome.

Why influenza can affect the heart

Fever and inflammation accelerate heart rate and increase oxygen demand. Dehydration, low blood oxygen and activation of coagulation add strain. In a person with atherosclerosis, infection may contribute to plaque disruption; in heart failure it can precipitate decompensation.

A self-controlled study in the New England Journal of Medicine identified 364 myocardial infarction admissions around laboratory-confirmed influenza. Twenty occurred during the first seven days —20 per week— compared with 344 during control periods —3.3 per week— for an incidence ratio of 6.05 (95% CI 3.86–9.50). The signal did not persist after day seven.

“Six times higher” describes a brief increase among people who had confirmed influenza and also experienced myocardial infarction within the study window. It does not mean that one in six people with influenza will have a heart attack, and it does not estimate absolute risk for a healthy individual.

How much the flu vaccine changes cardiovascular risk

The most widely quoted estimate comes from a meta-analysis of six randomised trials with 9,001 adults, a mean age of 65.5 years and 52.3% with a cardiac history. Mean follow-up was nine months. The composite included cardiovascular death, myocardial infarction, unstable angina, stroke, heart failure or urgent revascularisation.

NNV is the number needed to vaccinate to prevent one event during the study period. It is not a universal constant: it changes with viral circulation, strain match, vaccine formulation and baseline risk.

IAMI provides more direct evidence. It randomised 2,571 patients —99.7% after acute myocardial infarction— to inactivated influenza vaccine or placebo during admission. At 12 months, all-cause death, recurrent infarction or stent thrombosis occurred in 5.3% versus 7.2% (HR 0.72; 95% CI 0.52–0.99). The trial stopped before completing recruitment because of the pandemic, so the result is clinically important but does not remove uncertainty.

The accurate conclusion is not “the vaccine prevents one third of all heart attacks.” It is this: in people at high cardiovascular risk, particularly soon after an acute coronary syndrome, preventing influenza can translate into fewer events during the season.

Vaccines and cardiovascular prevention: a Spain-based decision table

US schedules should not simply be imported into Spain. This table summarises Spanish national recommendations current on 26 September 2026. Access and campaign logistics are organised by each autonomous community.

For shingles, see our dedicated guide to Shingrix, dementia and the limits of current evidence. Keeping that canonical separate prevents an emerging association from being confused with the more direct cardiovascular evidence for influenza vaccination.

A practical 2026–2027 protocol

1. Reconstruct your record. Note vaccines and approximate dates, recent infections, severe allergies, pregnancy, immunosuppression and previous reactions.
2. Define cardiac risk. Previous MI, ischaemic heart disease, heart failure and congenital heart disease are not equivalent to isolated hypertension. Diagnosis and severity affect eligibility.
3. Prioritise influenza. If you are in Spain’s target group, the usual adult schedule is one seasonal dose. The campaign begins in late September and October but remains available through the season.
4. Review COVID-19 separately. In 2026–2027 the general age threshold is 70, not 60; severe chronic heart disease and other risks are also included. A three-month minimum from a prior dose or documented infection is generally observed.
5. Use the same visit. Influenza, COVID-19 and other indicated vaccines may be coadministered at different anatomical sites. Systematically spacing every appointment is unnecessary.
6. Do not stop medication on your own. Antiplatelet or anticoagulant treatment may require an injection technique and local pressure, not an improvised interruption that raises thrombotic risk.

Situations that need an individual decision

Recent myocardial infarction or cardiovascular admission

IAMI vaccinated during admission, shortly after intervention or before discharge. That supports avoiding a missed opportunity, but it does not turn “within 72 hours” into a home rule. The treating team should confirm clinical stability, the current seasonal product and absence of a relevant contraindication.

Pregnancy

Spain recommends influenza vaccination in any trimester and prefers giving it during pregnancy; if missed, it may be offered up to six months postpartum. The 2026–2027 COVID-19 recommendation also includes all pregnant people, preferably in the second trimester although any trimester is acceptable.

Immunosuppression

Response may be lower and timing around treatment matters. Some live vaccines are contraindicated in particular immune deficiencies, whereas inactivated products may require a specific schedule. The answer is not to omit vaccination automatically but to coordinate it.

Egg allergy or a previous reaction

Egg allergy alone does not prevent influenza vaccination. Anaphylaxis after a previous dose or to a particular component does require review of the product and administration setting. Spanish guidance recommends 30 minutes of supervision after a severe allergic reaction.

Risks and red flags

Injection-site pain, fatigue, headache, low-grade fever or muscle aches for a day or two are expected reactions. Serious events are uncommon, but profiles differ by product and age. Guillain-Barré syndrome has been reported very rarely after some vaccines; a previous history warrants a clinical discussion.

• Call 112: breathing difficulty, swelling of the face or throat, generalised hives, collapse, persistent pressure-like chest pain, one-sided weakness or sudden speech difficulty.
• Seek same-day assessment: new or worsening breathlessness, sustained palpitations, fainting, persistent high fever or progressive weakness.
• Arrange routine review: a local reaction worsening after 48 hours, uncertainty about a previous dose or the need to rebuild an incomplete schedule.

Red flags do not prove that vaccination caused the problem. Temporal sequence and causality are different; important symptoms are assessed first and attributed later.

What vaccination does not replace

Vaccination does not correct high blood pressure, raised LDL or ApoB, smoking or inactivity. To order those layers, start with our guide to preventive medicine, understand what ApoB adds and review when a coronary calcium score can change a decision.

After 70, a vaccine does not settle decisions about preventive medication either: our analysis of STAREE and statins explains absolute benefit and limitations. With sudden symptoms, the priority remains recognising possible stroke or TIA and activating emergency care.

At Progevita, a useful preventive review is not about accumulating interventions. It is about listening, measuring real risk, identifying what is missing, setting priorities and coordinating continuity with primary care and specialists. Your health centre and regional schedule remain the reference for access to recommended vaccines.

Frequently asked questions about flu vaccination and heart health

Does the flu vaccine prevent heart attacks?

It prevents influenza and its complications and was associated with fewer cardiovascular events in trials of high-risk cardiac patients. It cannot guarantee that an individual will not have a heart attack, and absolute benefit depends strongly on baseline risk.

How much does it reduce cardiovascular risk?

Across six trials with 9,001 adults, events occurred in 3.6% with vaccination and 5.4% with control: a 1.8-point difference and an approximate NNV of 56. The difference was 4.5 points after recent acute coronary syndrome; stable outpatients showed no difference.

Who should receive a flu vaccine in Spain in 2026–2027?

Everyone aged 60 or older and people aged 5–59 with risk conditions such as chronic cardiovascular disease. Pregnancy and additional public-health groups are also included.

Can I receive it after a heart attack?

It is usually indicated if you have not received that season’s dose. IAMI gave it during admission, but your care team should choose the exact timing according to clinical stability.

Can flu and COVID-19 vaccines be given together?

Yes. They may be coadministered, preferably at different anatomical sites. The same review can assess pneumococcal, RSV and shingles eligibility.

Which vaccines should someone with heart disease review?

Influenza, COVID-19, pneumococcal, RSV and shingles according to age, type of heart disease, immune status and previous doses. They are not all annual and heart disease does not trigger one identical schedule.

Does egg allergy prevent influenza vaccination?

Not generally. Spain permits vaccination without extra special precautions. A severe previous reaction to a vaccine or one of its components needs specific assessment.

Which symptoms require urgent care?

Breathing difficulty, facial or throat swelling, generalised hives or collapse suggest a severe allergic reaction. Persistent chest pain, severe breathlessness, fainting or stroke signs are emergencies regardless of vaccination.

Sources

1. Spanish Ministry of Health. Influenza vaccination recommendations, 2026–2027 season.
2. Spanish Ministry of Health. COVID-19 vaccination recommendations, 2026–2027.
3. Spanish Interterritorial Council. Risk-based adult immunisation schedule, 2026.
4. Heidenreich PA et al. Adult Immunizations as Part of Cardiovascular Care. JACC. 2026.
5. European Society of Cardiology. Vaccination as a form of cardiovascular prevention. Clinical consensus, 2025.
6. Kwong JC et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. NEJM. 2018.
7. Behrouzi B et al. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Network Open. 2022.
8. Fröbert O et al. Influenza Vaccination After Myocardial Infarction: IAMI. Circulation. 2021.

Method: narrative review of the linked guidelines, official recommendations and trials. Cardiovascular estimates include population, comparator and limitations and are not extrapolated to low-risk adults. Sources checked 26 September 2026. Educational content; it does not replace an individual recommendation or your regional immunisation schedule.

Commercial disclosure: Progevita provides preventive assessment and follow-up. This guide does not sell vaccines or present vaccination as a substitute for primary care, cardiovascular treatment or healthy behaviours.